BNTC News
Archived Headlines
- Microcap biotech Benitec Biopharma revives US IPO with 61% lower deal size and warrants 08/10/15
- Week ahead: 10 IPOs set to price during the week of August 3 08/02/15
- Hepatitis C biotech Benitec Biopharma sets terms for $65 million IPO 07/27/15
- Gene therapy biotech Benitec Biopharma files for a $70 million US IPO 06/22/15
Silenced: RNA biotech Silenseed withdraws $35 million IPO
Silenseed, a biotech developing RNA interference cancer drugs and delivery systems, withdrew its plans for an initial public offering on Tuesday. The company has first targeted pancreatic cancer for its combined RNA interference (RNAi) drug and delivery...read more
US IPO Weekly Recap: One IPO and one bad week in the markets
Equity Selloff Hits Recent IPOs Recent IPOs have not been exempt from the steep selloff in the major indices. As of midday Friday, the Renaissance IPO Index was down 5...read more
Benitec Biopharma prices significantly downsized US IPO at $9.21
Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, raised $14 million by offering 1.5 million ADSs at $9.21. Each ADS was sold with one third of a warrant to purchase an ADS at a $5.50 exercise price. The...read more
Microcap biotech Benitec Biopharma decreases proposed IPO deal size to $15 million
Benitec Biopharma, which is developing a gene therapy platform based on DNA-directed RNA interference, reduced the number of ADSs it plans to offer for the second time and reduced the number of warrants offered. The Balmain, Australia-based company...read more